Specialty pharmaceutical company Horizon Pharma has commenced the full commercial launch of Rayos (Prednisone) delayed-release tablets for rheumatology indications, such as rheumatoid arthritis and polymyalgia rheumatica. Rayos is a ...
Tags: Horizon Pharma, Rayos, delayed-release tablets, rheumatology indications
The US Patent and Trademark Office (USPTO) has granted notice of allowance (NOA) to SkyePharma for a patent application 2012/0177734 of RAYOS (Prednisone) delayed-release tablets. The NOA covers the FDA-approved RAYOS, which uses the ...
Tags: SkyePharma, RAYOS delayed-release tablets, rheumatoid arthritis